相关实验视频
Updated: May 11, 2025

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.4K
对于接受GLP-1受体激动剂接受选择性手术的患者的吸收风险和战略方法
Juan Li1, Basma Mohamed2, Shun Huang3
1Division of Cardiothoracic Anesthesia, Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Current medical research and opinion
|April 17, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 的周围手术管理是复杂的. 本综述建议使用胃超声波来评估个性化GLP-1 RA外科手术管理的吸收风险.
科学领域:
- 麻醉学 麻醉学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 葡萄糖类-1受体激动剂 (GLP-1RA) 越来越多地使用,这在外科手术期间的管理中带来了挑战.
- 最近关于吸气和肺部并发症的担忧导致了指导方针的制定,但证据仍然有限.
研究的目的:
- 审查关于GLP-1RA外科手术期间管理的现有文献.
- 专注于与GLP-1RA相关的吸收风险.
- 推一个术后管理策略,包括胃超声波.
主要方法:
- 对当前文学进行叙述性回顾.
- 对GLP-1RA和术后结果的研究分析.
- 评价胃超声波在决策中的作用.
主要成果:
- 缺乏强有力的证据支持持有或继续持有GLP-1RA的最终建议.
- 目前的指导方针给临床医生带来了不确定性.
- 个性化风险评估对于愿望至关重要.
结论:
- 对GLP-1RA的外科治疗需要平衡吸收风险与药物停用或手术延迟的潜在不良结果.
- 胃超声波可以帮助个性化风险评估手术患者在GLP-1RA.
相关概念视频
Glucagon-like Receptor Agonists
264
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
264
Oral Hypoglycemic Agents: Glinides
109
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109
Hypoglycemia and Glucagon
139
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
139
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
31
Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
31
Dipeptidyl Peptidase 4 Inhibitors
128
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
128
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
113
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
113

